Clinically relevant fatigue in men with hormonesensitive prostate cancer on long-term androgen deprivation therapy

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1542-1549

  Storey, D J ^a,b   McLaren, D B ^b   Atkinson, M A ^b   Butcher, I ^a   Frew, L C ^c   Smyth, J F ^a   Sharpe, M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c QUEEN MARGARET HOSPITAL   (United Kingdom)

Author keywords

Androgen deprivation; Cancer; Fatigue; Hormone; Prostate

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRIEF PAIN INVENTORY; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; FATIGUE; HORMONE SENSITIVITY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SYMPTOMATOLOGY; TREATMENT DURATION; UNITED KINGDOM;

EID: 84861741990     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr447     Document Type: Article

References (42)

1. Cancer Research UK. UK Cancer Incidence Statistics for Common Cancers. 2011; http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/ (4 May 2011, date last accessed).
2. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-108.
3. Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 2004; 14(3): 177-183.
4. Stone P, Hardy J, Huddart R et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36: 1134-1141.
5. Potosky AL, Reeve BB, Clegg LX et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002; 94(6): 430-437.
6. Potosky AL, Knopf K, Clegg LX et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 3750-3757.
7. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000; 163(6): 1743-1746.
8. Van Andel G, Kurth KH. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 2003; 44(2): 209-214.
9. Pirl WF, Greer JA, Goode M, Smith MR. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology 2008; 17: 148-153.
10. Hussain S, Gunnell D, Donovan J et al. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int 2008; 101: 547-555.
11. SIMD. Scottish Index of Multiple Deprivation 2004; http://www.scotland.gov.uk/Publications/2004/06/19421/38085andhttp://www.scotland.gov.uk/Topics/Statistics/SIMD (22 July 2011, date last accessed).
12. Lilleby W, Fossa SD, Waehre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 735-743.
13. Mendoza TR, Wang XS, Cleeland CS et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999; 85: 1186-1196.
14. Hwang SS, Chang VT, Cogswell J, Kasimis BS. Clinical relevance of fatigue levels in cancer patients at a Veterans Administration Medical Center. Cancer 2002; 94: 2481-2489.
15. Cleeland CS, Wang XS. Measuring and understanding fatigue. Oncology 1999; 13: 91-97.
16. Mock V. Fatigue management: evidence and guidelines for practice. Cancer 2001; 92: 1699-1707.
17. NCCN. Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue v. 1. 2009. http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf. (4 May 2011, date last accessed).
18. Husain AF, Stewart K, Arseneault R et al. Women experience higher levels of fatigue than men at the end of life: a longitudinal home palliative care study. J Pain Symptom Manage 2007; 33: 389-397.
19. Dimeo F, Schwartz S, Wesel N et al. Effects of an endurance and resistance exercise program on persistent cancer-related fatigue after treatment. Ann Oncol 2008; 19: 1495-1499.
20. Cleeland CS, Chapman CR, Loeser JD. Measurement of pain by subjective report. In Chapmanand CR, Loeser JD (Eds) Advances in Pain Research and Therapy, Volume 12: Issues in Pain Measurement. New York: Raven Press 1989; 391-403.
21. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67(6): 361-370.
22. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52: 69-77.
23. Fossa SD, Woehre H, Kurth KH et al. Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol 1997; 31 (SUPPL): 3-8.
24. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85(5): 365-376.
25. Fayers P, Aaronson N, Bjordal K et al. EORTC QLQ-C30 Scoring Manual. Brussels, Belgium: EORTC 2001.
26. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16(1): 139-144.
27. Michelson H, Bolund C, Nilsson B, Brandberg Y. Health-related quality of life measured by the EORTC QLQ-C30-reference values from a large sample of Swedish population. Acta Oncol 2000; 39: 477-484.
28. Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 2001; 37: 1345-1351.
29. Aktas A, Walsh D, Rybicki L. Symptom clusters: myth or reality? Palliat Med 2010; 24: 373-385.
30. Storey DJ, Waters RA, Hibberd CJ et al. Clinically relevant fatigue in cancer outpatients: the Edinburgh Cancer Centre symptom study. Ann Oncol 2007; 18(11): 1861-1869.
31. Storey DJ, McLaren DB, Atkinson MA et al. Clinically relevant fatigue in recurrence-free prostate cancer survivors. Ann Oncol 2012; 23: 65-72.
32. Shores MM, Sloan KL, Matsumoto AM et al. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry 2004; 61: 162-167.
33. Jakobsson L, Loven L, Hallberg IR. Micturition problems in relation to quality of life in men with prostate cancer or benign prostatic hyperplasia: comparison with men from the general population. Cancer Nurs 2004; 27(3): 218-229.
34. Alibhai SMH, Breunis H, Timilshina N et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 2010; 28: 5038-5045.
35. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006; 332(7549): 1080.
36. Strum SB, McDermed JE, Scholz MC et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997; 79(6): 933-941.
37. Ornstein DK, Beiser JA, Andriole GL. Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int 1999; 83(1): 43-46.
38. Segal RJ, Reid RD, Courneya KS et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003; 21: 1653-1659.
39. Windsor PM, Nicol KF, Potter J. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radial external beam radiotherapy for localized prostate carcinoma. Cancer 2004; 101: 550-557.
40. Ling CHY, Taekema D, de Craen AJM et al. Handgrip strength and mortality in the oldest old population: the Leiden 85-plus study. CMAJ 2010; 182: 429-435.
41. Roth AJ, Nelson C, Rosenfeld B et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer 2011; 116: 5102-5110.
42. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer